<DOC>
	<DOCNO>NCT01261962</DOCNO>
	<brief_summary>In leukocyte patient undergo adjuvant chemotherapy colon cancer treatment : ) identify gene modulate oral supplementation zinc ; b ) evaluate effect oral zinc supplementation humoral immunity neutrophil function . The study conduct 30 adult patient age grater 18 year , gender undergo surgical resection colonic neoplastic lesion without metastatic lesion . Patients randomize two group , first ( Group QT Zn , n = 15 ) receive 70 mg/d zinc 16 week second receive placebo ( QT Placebo Group , n = 15 ) . The study also include 30 healthy volunteer receive supplementation 70 mg/d Zn ( C Zn group , n = 15 ) placebo ( Group C Placebo , n = 15 ) . Zinc supplementation placebo study group start two day volunteer receive pneumococcal vaccine , polyvalent 23 . Fifteen day vaccination , patient begin chemotherapy pre-established criterion Oncology Service . Will monitor parameter nutritional status ( anthropometry , bioelectrical impedance , food intake , laboratory test ) adverse effect , accord rule CTCAE . In evaluation humoral immunity , antibody opsonization pneumococcal polysaccharide measure . Will evaluate function neutrophil measure DNA NETs quantify calprotectin elastase release culture supernatant activate neutrophil . RT-qPCR do gene differentially express ( DEGS ) activate leukocyte . In six volunteer group analyze global gene expression RNA extract leukocyte microarray ; detect correlate molecular pathway modulate zinc MetaCore software ( GeneGo ) . The DEGS validate RT-qPCR .</brief_summary>
	<brief_title>Modulation Immune Response Oral Zinc Supplementation Chemotherapy Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Age great 18 year Diagnostic histopathology colon cancer stage III ( Dukes ' stage C ) Performance Scale Karnofsky great equal 70 % Have subject resection primary neoplastic lesion 8 week start chemotherapy Patient first cycle chemotherapy adjuvant XELOX regimen . Patients history autoimmune inflammatory disease , active infectious disease , liver disease , renal failure diabetes mellitus Patients metastatic disease Have previously receive radiotherapy chemotherapy Use GCSFGranulokine Â® ( growthstimulating factor granulocyte ) Use immunosuppressive drug , diuretic supplement zinc copper .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Humoral immunity</keyword>
	<keyword>Neutrophil function</keyword>
	<keyword>Gene expression</keyword>
</DOC>